{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:04:51Z","timestamp":1763787891731,"version":"3.45.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170327","82370332"],"award-info":[{"award-number":["82170327","82370332"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clinthera.2025.06.015","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T19:48:19Z","timestamp":1752781699000},"page":"798-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Direct Oral Anticoagulants for Patients With Atrial Fibrillation With Glomerular Hyperfiltration: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Xinyi","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.06.015_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034573","article-title":"Trends in oral anticoagulant prescribing in individuals with type 2 diabetes mellitus: a population-based study in the UK","volume":"10","author":"Alwafi","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.hrthm.2020.01.007","article-title":"Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: a population-based cohort study","volume":"17","author":"Mongkhon","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.10.025","article-title":"Oral anticoagulants and risk of dementia: a systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"96","author":"Mongkhon","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-9560-11-18","article-title":"The new oral anti-coagulants and the phase 3 clinical trials\u2014a systematic review of the literature","volume":"11","author":"Tahir","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116303","article-title":"Hip fractures risks in edoxaban versus warfarin users: a propensity score-matched population-based cohort study with competing risk analyses","volume":"156","author":"Zhou","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/heartjnl-2022-321377","article-title":"Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014\u20132019)","volume":"109","author":"Joy","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0007","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0008","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/ndt\/gfr651","article-title":"Glomerular hyperfiltration in prediabetes and prehypertension","volume":"27","author":"Okada","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.03470412","article-title":"Relationship between GFR and albuminuria in stage 1 hypertension","volume":"8","author":"Palatini","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0010","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/osp4.365","article-title":"Prevalence of hyperfiltration among US youth\/young adults with overweight and obesity: a population-based association study","volume":"5","author":"Turer","year":"2019","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0012","first-page":"2137","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0013","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/eurheartj\/ehac450","article-title":"Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?","volume":"44","author":"Huqi","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107123","article-title":"The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function\u2014a systematic review","volume":"147","author":"Huqi","year":"2022","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0015","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0016","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/ndt\/gfy332","article-title":"Comparison of high glomerular filtration rate thresholds for identifying hyperfiltration","volume":"35","author":"Chakkera","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2215\/CJN.03080314","article-title":"A systematic review of glomerular hyperfiltration assessment and definition in the medical literature","volume":"10","author":"Cachat","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0018","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0019","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.116.024666","volume":"135","author":"Lindner","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0021","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.amjmed.2017.04.015","article-title":"Renal function considerations for stroke prevention in atrial fibrillation","volume":"130","author":"Fanikos","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0022","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0023","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/BRS.0b013e3181b1c99f","article-title":"2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group","volume":"34","author":"Furlan","year":"2009","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0024","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0025","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0026","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1161\/STROKEAHA.118.024264","article-title":"Non-vitamin K antagonist oral anticoagulants in Asian patients with supranormal renal function","volume":"50","author":"Lee","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0027","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1080\/03007995.2017.1339674","article-title":"Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence","volume":"33","author":"Weir","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006515","article-title":"Comparative effectiveness and safety of oral anticoagulants across kidney function in patients with atrial fibrillation","volume":"13","author":"Yao","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0029","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/STROKEAHA.118.021387","article-title":"Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation","volume":"49","author":"Yu","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0030","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1046\/j.1523-1755.1998.00217.x","article-title":"Temporal relationships between hormonal and hemodynamic changes in early human pregnancy","volume":"54","author":"Chapman","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-0528.1981.tb00929.x","article-title":"Serial changes in renal haemodynamics during normal human pregnancy","volume":"88","author":"Dunlop","year":"1981","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0032","first-page":"F132","article-title":"Effect of amino acid infusion on renal hemodynamics in humans","volume":"251","author":"Castellino","year":"1986","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0033","first-page":"F613","article-title":"Human renal response to meat meal","volume":"250","author":"Hostetter","year":"1986","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0034","doi-asserted-by":"crossref","first-page":"f324","DOI":"10.1136\/bmj.f324","article-title":"Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis","volume":"346","author":"Nitsch","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0035","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0036","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0037","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0038","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0039","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1053\/j.ackd.2010.05.010","article-title":"Estimating the glomerular filtration rate in obese adult patients for drug dosing","volume":"17","author":"Pai","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0040","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2215\/CJN.06870909","article-title":"Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size","volume":"5","author":"Michels","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0041","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0042","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the \u2018Atrial Fibrillation Better Care\u2019 pathway in patients with atrial fibrillation: impact on clinical outcomes\u2014a systematic review and meta-analysis of 285,000 patients","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2025.06.015_bib0043","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 Focused update consensus guidelines of the Asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T05:02:40Z","timestamp":1763787760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0149291825002218"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Direct Oral Anticoagulants for Patients With Atrial Fibrillation With Glomerular Hyperfiltration: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}